Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment
研究单位：[1]Shanghai Junshi Bioscience Co., Ltd.[2]The Fifth Medical Center of PLA General Hospital,Beijing,Beijing,China,100071[3]Beijing Hospital,Beijing,Beijing,China[4]Chinese PLA General Hospital,Beijing,Beijing,China[5]Peking University Shougang Hospital,Beijing,Beijing,China[6]Affiliated Hospital of Hebei University,Baoding,China[7]The first affiliated Hospital of Bengbu Medical College,Bengbu,China[8]Jilin Cancer Hospital,Changchun,China[9]The First Hospital of Jilin University,Changchun,China[10]Hunan Cancer Hospital,Changsha,China[11]Affiliated Hospital of Chengde Medical University,Chengde,China[12]Sichuan Cancer Hospital,Chengdu,China[13]Chongqing Cancer Hospital,Chongqing,China[14]The Second Hospital of Dalian Medical University,Dalian,China[15]The First People's Hospital of Foshan,Foshan,China[16]Fujian Medical University Union Hospital,Fuzhou,China[17]Guangdong General Hospital,Guangzhou,China[18]Sun Yat-sen Memorial Hospital, Sun Yat-sen University,Guangzhou,China[19]Sun Yat-sen University Cancer Center,Guangzhou,China[20]The First Affiliated Hospital, Sun Yat-sen University,Guangzhou,China[21]The Women and Children''s Hospital of Guangdong Province,Guangzhou,China[22]The First Affiliated Hospital Zhejiang University,Hangzhou,China[23]The Second Affiliated Hospital of Zhejiang University School of Medicine,Hangzhou,China[24]Zhejiang Cancer Hospital,Hangzhou,China[25]Harbin Medical University Cancer Hospital,Harbin,China[26]Anhui Province Hospital & The First Affiliated Hospital of USTC,Hefei,China[27]The First Affiliated Hospital of Anhui Medical University,Hefei,China[28]The Second Hospital of Anhui Medical University,Hefei,China[29]Shandong Cancer Hospital,Jinan,China[30]Yunnan Cancer Hospital,Kunming,China[31]Linyi Cancer Hospital,Linyi,China[32]The Affiliated Hospita of of Southwest Medical University,Luzhou,China[33]Jiangxi Cancer Hospital,Nanchang,China[34]The Third Hospital of Nanchang,Nanchang,China[35]Jiangsu Cancer Hospital,Nanjing,China[36]Jiangsu Province Hospital,Nanjing,China[37]The Affiliated Hospital of Qingdao University,Qingdao,China[38]Changhai Hospital,Shanghai,China[39]Shanghai General Hospital,Shanghai,China[40]Liaoning Cancer Hospital&Intitute,Shenyang,China[41]The First Hospital of China Medical University,Shenyang,China[42]The Fourth Hospital of Hebei Medical University,Shijiazhuang,China[43]Cancer Hospital Affiliated to Xinjiang Medical University,Urumqi,China[44]Hubei Cancer Hospital,Wuhan,China[45]Tongji Hospital Tongji Medical College Huazhong University of Science and Technology,Wuhan,China[46]Union Hospital Tongji Medical College Huazhong University of Science and Technology,Wuhan,China[47]Affiliated Hospital of Jiangnan University（Wuxi NO.4 People''s Hospital）,Wuxi,China[48]The First Affiliated Hospital of Xiamen University,Xiamen,China[49]Xiangyang Central Hospital,Xiangyang,China[50]The First Affiliated Hospital of Xi''an Jiaotong University,Xian,China[51]The Second Affiliated Hospital of The PLA Air Force Military Medical University,Xian,China[52]General Hospital of Ningxia Medical University,Yinchuan,China[53]Henan Provincial People''s Hospital,Zheng''zhou,China[54]Henan Cancer Hospital,Zhengzhou,China
研究目的：
This multicenter, randomized, double-blind study will evaluate the efficacy and safety of Toripalimab (JS001) combined with nab-paclitaxel compared with placebo combined with nab-paclitaxel for first/second line treatment of metastatic or recurrent triple-negative breast cancer (TNBC).
